Wang Pei-Ning, Lin Kun-Ju, Liu Huei-Chun, Andreasson Ulf, Blennow Kaj, Zetterberg Henrik, Yang Shieh-Yueh
Department of Neurology Neurological Institute Taipei Veterans General Hospital Taipei Taiwan.
Department of Neurology School of Medicine National Yang-Ming University Taipei Taiwan.
Alzheimers Dement (Amst). 2020 Apr 30;12(1):e12029. doi: 10.1002/dad2.12029. eCollection 2020.
Pyroglutamate-modified amyloid β (Aβ) could be a biomarker for Aβ plaque pathology in the brain. An ultra-high-sensitive assay is needed for detecting Aβ.
Immunomagnetic reduction was used for quantification of Aβ in plasma from 46 participants. The concentrations of Aβ of these subjects were compared with F-florbetapir positron emission tomography (PET) images.
Aβ concentration was 44.1 ± 28.2 fg/mL in PET- (n = 28) and 91.6 ± 54.6 fg/mL in PET+ (n = 18; < .05). The cutoff value of Aβ for discriminating PET- from PET+ was 55.5 fg/mL, resulting in a sensitivity of 83.3%, a specificity of 71.4%. The concentration of Aβ showed a moderate correlation (r = 0.437) with PET standardized uptake value ratio.
We did not enroll pre-clinical AD subject with normal cognition but Aβ PET+. It would be an important issue to explore the feasibility of using Aβ for screening pre-clinical subjects.
These results reveal the feasibility of detecting Aβ pathology using quantification of a plaque-derived Aβ molecule in plasma.
焦谷氨酸修饰的淀粉样β蛋白（Aβ）可能是大脑中Aβ斑块病理学的生物标志物。检测Aβ需要一种超高灵敏度的检测方法。
采用免疫磁珠法对46名参与者血浆中的Aβ进行定量。将这些受试者的Aβ浓度与F-氟代苯并噻唑正电子发射断层扫描（PET）图像进行比较。
PET-组（n = 28）的Aβ浓度为44.1±28.2 fg/mL，PET+组（n = 18；P <.05）为91.6±54.6 fg/mL。区分PET-和PET+的Aβ临界值为55.5 fg/mL，灵敏度为83.3%，特异性为71.4%。Aβ浓度与PET标准化摄取值比值呈中度相关（r = 0.437）。
我们未纳入认知正常但Aβ PET+的临床前AD受试者。探索使用Aβ筛查临床前受试者的可行性将是一个重要问题。
这些结果揭示了通过定量血浆中斑块衍生的Aβ分子来检测Aβ病理学的可行性。
